Gold Price Outlook Could 6000 Be on the Horizon for 2026 Brookings Study Examines Data Center Employment Impact on Local Economies Consumer Sentiment Hits Record Low as White House Disputes Survey Findings Michael Saylor Says Tokenization Could Create Free Market for Yield and Credit BP Chairman Abruptly Removed Amid Allegations of Bullying and Overbearing Conduct SpaceX Goes Public The Critical Milestone for a Potential 15 Trillion Valuation Haemonetics Q1 2026 Earnings EPS Slightly Above Estimates Stock Gains 57 IEP Q1 2026 Earnings Massive EPS Miss Amid Operational Challenges CLOV Q1 2026 Earnings EPS Surges Past Estimates Stock Jumps 16 FFBC Q1 2026 Earnings EPS Beats Estimates by 803 Shares Dip 109 PTC Q1 2026 Earnings Strong EPS Beat Fuels Cautious Optimism Amid Slight Stock Dip RCI Hospitality Holdings RICK Q3 2025 Earnings EPS Misses Estimates by a Wide Margin Uranium Royalty Corp UROY Gains 246 as Nuclear Sentiment Lifts Uranium Exposure Dycom Industries DY Nears Support After Modest Decline BlackRock Virginia Municipal Bond Trust BHV Holds Steady at 1133 Amidst Flat Trading Session Pediatrix Medical Group MD Holds Steady Near Resistance Consolidation Phase Ahead Power Solutions International PSIX Faces Selling Pressure as Key Support Levels Come into Focus Tony Blairs Economic Prescription for Britain Accurate Diagnosis Questionable Remedies Central Garden Pet Company CENTA Q1 2026 Earnings Strong EPS Beat Driven by Operational Efficiency Gladstone Investment 4875 Notes GAINZ Stability Amidst Flat Trading Yield Opportunity in Focus Political Churn Could Signal Market Uncertainty The Rise of Andy Burnham and Progressive Policy Risks Trump EPAs PFAS Destruction Plan Draws Industry and Health Concerns Diamondback Energy Poised to Benefit from Recent Oil Price Shocks Japans Megabanks Report Record Profits Amid Rising Credit and Geopolitical Risks Qfin QFIN Q3 2025 Earnings Call Transcript Released Market Participants Scrutinise Management Commentary Pfizer Prevails in Singapore Trademark Dispute with Merck Over Vaccine Brand Rail Vikas Nigam Q4 FY26 Results Net Profit Drops 59 YoY Despite Revenue Growth